Skip to main content
. Author manuscript; available in PMC: 2023 Jun 1.
Published in final edited form as: Gynecol Oncol. 2022 Mar 31;165(3):568–576. doi: 10.1016/j.ygyno.2022.03.018

Figure 3.

Figure 3.

A. Methylation intensity of top 11 OC MDMs in plasma within the plasma-based clinical pilot. Black boxes indicate values of B3GALT6-normalized MDM qMSP product below the control samples’ 95th percentile. For products above that threshold, increasing deciles of intensity are depicted on a yellow-red color spectrum. Each row is a candidate MDM, each column is a patient sample. B. In plasma, the 11-MDM panel discriminated between OC cases and healthy controls with an AUC of 0.91.